Gene Therapy for X-linked Chronic Granulomatous Disease (X-CGD)

Overview

X-linked chronic granulomatous disease (X-CGD) is a rare genetic disorder, which affects boys. It is caused by an error in a gene that makes part of the immune system. The basic defect lies in specialised white blood cells called phagocytic cells (or phagocytes), which are responsible for protection against infection by destroying invading bacteria and fungi. They do this by pouring large amounts of substances similar to bleach onto these organisms. In CGD, there is a defect in the system that makes the bleach, called the NADPH-oxidase. In X-CGD (which accounts for two thirds of patients), the defect lies in a gene which makes up a critical part of the NADPH-oxidase (known as gp91-phox), and the cells cannot make bleach-like substances. Therefore they kill bacteria and fungi poorly, and the patients suffer from severe and recurrent infections. This also results in inflammation which can damage parts of the body such as the lung and gut. In many cases, patients can be adequately protected from infection by constant intake of antibiotics. However, in others, severe life-threatening infections break through. In some cases, inflammation in the bowel or urinary systems results in blockages which cannot be treated with antibiotics, and which may require the use of other drugs such as steroids. Development of curative treatments for CGD is therefore of great importance.

Full Title of Study: “A Phase I/II, Non Randomized, Multicenter, Open-label Study of Autologous CD34+ Cells Transduced With the G1XCGD Lentiviral Vector in Patients With X-linked Chronic Granulomatous Disease”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: September 2032

Interventions

  • Genetic: X vivo gene therapy
    • Transplantation of patient’s autologous CD34+ cells transduced with lentiviral vector containing GP91PHOX gene

Arms, Groups and Cohorts

  • Experimental: Open label
    • X vivo gene therapy

Clinical Trial Outcome Measures

Primary Measures

  • Safety of the procedure as measured by the incidence of adverse events
    • Time Frame: 24 months
  • Restoration and stability over time of the NADPH functioning granulocytes assessed by a DHR test
    • Time Frame: 12 months

Secondary Measures

  • Normalisation of nutritional status, growth, development, severe infection and/or inflammatory complication which recommended patient’s inclusion
    • Time Frame: 24 months
  • Percentage of transduced CD34+ haematopoietic cells infused and of blood cells over time
    • Time Frame: 24 months
  • Immunological reconstitution
    • Time Frame: 24 months

Participating in This Clinical Trial

Inclusion Criteria

  • Male X-CGD patients – Molecular diagnosis confirmed by DNA sequencing – At least one prior ongoing or resistant severe infection and/or inflammatory complications requiring hospitalisation despite conventional therapy – No HLA-matched donor available after 3 months search unless the risk of waiting for a potential match or for performing an allogeneic transplant is considered unacceptable by the investigator Exclusion Criteria:

  • Contraindication for leukapheresis – Contraindication for administration of conditioning medication – Administration of gammainterferon within 30 days before the infusion of transduced autologous CD34+ cells

Gender Eligibility: Male

Minimum Age: 6 Months

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Genethon
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Adrian Thrasher, MD, PHD, Principal Investigator, Great Ormond Street Hospital NHS Foundation Trust – London – UK
    • Janine Reichenbach, MD, Principal Investigator, University Children’s Hospital Zürich – Switzerland
    • Hubert Serve, MD, PHD, Principal Investigator, Department of Hematology/Oncology, University Hospital Frankfurt and Institute for Biomedical Research, Georg-Speyer-Haus, Frankfurt – Germany
    • Emma Morris, MD, PHD, Principal Investigator, Royal Free Hospital / University College London Hospital (UCLH)

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.